Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Boston Scientific (BSX – Research Report) and DaVita (DVA – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Boston Scientific (BSX)
Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific today and set a price target of $124.00. The company’s shares closed last Monday at $91.87.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $122.00, representing a 31.0% upside. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
See today’s best-performing stocks on TipRanks >>
DaVita (DVA)
Barclays analyst Andrew Mok CFA maintained a Hold rating on DaVita today and set a price target of $158.00. The company’s shares closed last Monday at $111.19.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on DaVita is a Moderate Sell with an average price target of $142.67, implying a 30.8% upside from current levels. In a report issued on January 19, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $109.00 price target.
